Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
65.2 ^USD	-1.12%		-2.73%	-19.52%

Apr. 29	Barclays Adjusts Price Target on Gilead Sciences to $76 From $80	MT
Apr. 26	TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV	Apr. 26	CI
News Highlights : Top Company News of the Day - Friday at 1 AM ET	Apr. 26	DJ
News Highlights : Top Company News of the Day - Thursday at 11 PM ET	Apr. 25	DJ
News Highlights : Top Company News of the Day - Thursday at 9 PM ET	Apr. 25	DJ
News Highlights : Top Company News of the Day - Thursday at 5 PM ET	Apr. 25	DJ
News Highlights : Top Company News of the Day - Thursday at 7 PM ET	Apr. 25	DJ
Gilead Sciences Q1 Tops Estimates, Updates Outlook	Apr. 25	MT
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges	Apr. 25	DJ
(GILD) GILEAD SCIENCES Forecasts Fiscal Year 2024 EPS Range $3.45 - $3.85	Apr. 25	MT
Earnings Flash (GILD) GILEAD SCIENCES Reports Q1 Revenue $6.69B, vs. Street Est of $6.348B	Apr. 25	MT
Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.	Apr. 25	CI
Gilead Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Gilead posts quarterly loss, revenue rises 5%	Apr. 25	RE
Gilead Sciences, Inc. Revises Earnings Guidance for the Full Year 2024	Apr. 25	CI
Gilead Sciences, Inc. Declares a Dividend for the Second Quarter of 2024, Payable on June 27, 2024	Apr. 25	CI
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	Apr. 19	MT
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years	Apr. 02	MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration	Apr. 02	DJ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences	Apr. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Highlights

Filters